GE has launched its first product in partnership with the biotechnology medical testing company Bionime, a home device for diabetics called the GE100 Blood Glucose Monitoring System.
GE has launched its first product in partnership with the biotechnology medical testing company Bionime, a home device for diabetics called the GE100 Blood Glucose Monitoring System.
The GE100 utilizes advanced patented strip technology to achieve a high level of accuracy and precision and a unique, innovative strip design that makes it easier to use and more sanitary for the consumer than current similar offerings, according to the company’s press release.
The company also said it hopes to continue to develop products with Bionime that will attack the global problem of type 2 diabetes, which GE calls the fastest growing chronic disease in the world.
“We are very excited to work with Bionime to provide innovative blood glucose monitoring for diabetes patients worldwide,” David Ataide, general manager, Strategic & Customer Initiatives, GE Healthcare, said in a press release. “Managing diabetes care is critical to the health of our society, and we believe this an important first step for our business.”
Bionime Chairman Roy Huang said in a statement that “by joining forces with GE, we can grow this vision by developing new offerings and widening the market for Bionime’s products.”
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.